# AIN and GN Diagnostic Methodologies: From Clinical Suspicion to Kidney Biopsy

## Introduction

The nephrologist’s first challenge in acute kidney injury is determining **why** the creatinine rose^([14](https://urinenephrology.org/mastery/aki-advanced/ain-gn-diagnostic-methodologies-review.html#verified-sources)). While acute tubular necrosis (ATN) and prerenal azotemia dominate the differential, the presence of an active urinary sediment and certain clinical clues demand investigation for acute interstitial nephritis (AIN) and glomerulonephritis (GN). These diagnoses carry fundamentally different management implications, prognostic trajectories, and treatment urgency.

This review synthesizes the diagnostic approach to AIN and GN in the acute setting—from bedside recognition through definitive biopsy interpretation—with practical algorithms for the experienced clinician.

------------------------------------------------------------------------

## 1. When AKI Is NOT ATN or Prerenal: Red Flag Recognition

### The Critical Importance of Urine Sediment Examination^([6](https://urinenephrology.org/mastery/aki-advanced/ain-gn-diagnostic-methodologies-review.html#verified-sources))

The urinalysis is the single most discriminating test in AKI diagnosis. An active sediment with casts immediately redirects thinking away from prerenal and ATN etiologies.

**Examination technique matters:** - Centrifuged, fresh sediment examined under **40× objective** (not dipstick alone) - Low-power field (LPF): RBCs, WBCs, bacteria, casts - High-power field (HPF): crystals, bacteria detail - **Always correlate with microscopy findings; dipstick findings without sediment confirmation are misleading**

### AIN: Red Flags

The classic triad of **rash, fever, eosinophilia** is present in only 10% of drug-induced AIN^([3,5](https://urinenephrology.org/mastery/aki-advanced/ain-gn-diagnostic-methodologies-review.html#verified-sources)). More commonly, presentation is insidious:

| Finding | Sensitivity | Specificity | Interpretation |
|----|----|----|----|
| **Sterile pyuria** | 80-90% | 60% | Essential screening finding; rules out infection |
| **WBC casts** | 40-70% | ~90% | Highly specific for AIN; tubulitis on biopsy |
| **Eosinophiluria** (Hansel stain) | 30.8% | 68.2% | **Do not order.** LR+ 0.97, LR− 1.01 — moves post-test probability essentially nowhere. PPV 15.6% |
| **Mild proteinuria** (\<1 g/day) | Variable | — | Distinguishes from nephrotic GN |
| **Elevated urine eosinophils** | — | — | **Wright-Giemsa less reliable than Hansel stain** |

**Drug timeline is critical:** - **Beta-lactam antibiotics (nafcillin, oxacillin):** 1–3 weeks exposure before AKI onset^([4,5](https://urinenephrology.org/mastery/aki-advanced/ain-gn-diagnostic-methodologies-review.html#verified-sources)) - **Sulfonamides, NSAIDs, fluoroquinolones:** Similar 1–3 week window - **PPIs (proton pump inhibitors):** Delayed, insidious onset; median 2–3 **months** of exposure; acute presentation rare (see ppi kidney report)^([8,9](https://urinenephrology.org/mastery/aki-advanced/ain-gn-diagnostic-methodologies-review.html#verified-sources)) - Checkpoint inhibitors: Variable, can occur weeks to months after initiation^([10](https://urinenephrology.org/mastery/aki-advanced/ain-gn-diagnostic-methodologies-review.html#verified-sources))

PPI-associated AIN is frequently missed because the temporal relationship is not obvious. Patients may have been on PPIs for years without incident. The absence of systemic symptoms (rash, fever, eosinophilia) makes clinical suspicion harder. When faced with unexplained AKI, always ask: “How long has the patient been on a PPI?”

### GN: Red Flags

Active glomerulonephritis announces itself with an active urinary sediment:

| Finding | Associated Diagnosis | Implication |
|----|----|----|
| **RBC casts** | GN (especially RPGN, crescentic) | Strongly supports glomerular bleeding; prompt serologic workup depends on the clinical presentation and kidney-function trajectory |
| **Dysmorphic RBCs** | GN (any type) | Glomerular origin of hematuria |
| **Proteinuria \>1 g/day** | Nephrotic-range proteinuria (MPGN, membranoproliferative types) | May coexist with rapidly progressive disease |
| **Hypertension + hematuria** | Lupus, ANCA, post-infectious GN | Hypertension in GN suggests immune injury/inflammation |
| **Hypocomplementemia** | Lupus, post-infectious GN, cryoglobulinemia, MPGN | Certain patterns narrow the differential dramatically |

------------------------------------------------------------------------

## 2. Diagnostic Approach to Acute Interstitial Nephritis^([1,3](https://urinenephrology.org/mastery/aki-advanced/ain-gn-diagnostic-methodologies-review.html#verified-sources))

### 2.1 History and Drug Timeline

The **timing of drug exposure is diagnostic.** A systematic medication history is essential:

    Timeline Template:
    ─────────────────────────────────────────
    [Start Drug A] ──── 10 days ──── [AKI Detected] ✓ Beta-lactam
    [Start Drug B] ──── 3 months ──── [AKI Detected] ✓ PPI
    [Start Drug C] ──── 1 week ──── [AKI Detected] ✓ NSAID

**Gather:** - Exact start date of each new medication - Any medication changes in the 3 months prior to AKI - Over-the-counter NSAIDs, herbal supplements (often forgotten) - Recent vaccinations (checkpoint inhibitors, rarely triggering AIN)

### 2.2 Urinalysis Pattern in AIN

**Expected findings (in order of diagnostic weight):**

1.  **Sterile pyuria** (WBC \>5 per HPF in absence of bacteria)
    - Present in 80–90% of drug-induced AIN
    - Must confirm absence of bacteria (urine culture negative)
    - Pyuria + positive culture = UTI, not AIN
2.  **WBC casts**
    - Hallmark finding; correlates with interstitial lymphocyte/eosinophil infiltration
    - When present with sterile pyuria, specificity approaches 90%
    - May see hyaline casts and fine granular casts
3.  **Eosinophiluria** (Hansel stain)^([2](https://urinenephrology.org/mastery/aki-advanced/ain-gn-diagnostic-methodologies-review.html#verified-sources))
    - **Hansel stain (methylene blue + safranin) \> Wright-Giemsa**
    - Sensitivity 30.8%, specificity 68.2% (Muriithi 2013, n=566 with paired biopsy). The decisive figures are the likelihood ratios: **LR+ 0.97 and LR− 1.01** — both at 1.0, so the result moves post-test probability essentially nowhere in either direction. PPV 15.6%, meaning most positives are false. Raising the cutoff to 5% drops sensitivity to 19.8% for specificity 91.2%. **Should not be ordered**^([2](https://urinenephrology.org/mastery/aki-advanced/ain-gn-diagnostic-methodologies-review.html#verified-sources))
    - **If positive, strongly supports AIN; if negative, does NOT exclude it**
    - Not routinely available; must request specifically
4.  **Mild proteinuria**
    - Typically \<1 g/day (often 0.5–1 g)
    - Helps distinguish from nephrotic GN
    - Dipstick may show 1+ or 2+ protein
5.  **RBCs**
    - Non-specific; present in variable amounts
    - If dysmorphic or in casts, suspect concurrent GN

### 2.3 Urine Biomarkers: B2-Microglobulin and Tubular Markers

See detailed review at B2M AIN Comprehensive Review.

**B2-microglobulin (B2M):** - Normal filtered load is reabsorbed by proximal tubule - Elevated urine B2M indicates proximal tubular dysfunction - In AIN, tubular infiltration and edema cause tubular leak - **Sensitivity 70–80%, specificity 70–80%** for AIN diagnosis when combined with clinical context - Not specific (also elevated in tubular diseases, early CKD)

**KIM-1 (Kidney Injury Molecule-1), NAG (N-acetyl-β-glucosaminidase):** - Research biomarkers for tubular injury - Not yet standard clinical practice

### 2.4 Historical: Gallium-67 Scan

Gallium-67 imaging was used to demonstrate interstitial accumulation; now largely replaced by kidney biopsy for diagnostic certainty. Rarely ordered in current practice.

### 2.5 PPI-Associated AIN: A Special Case

See detailed review at ppi kidney report.

**Distinguishing features of PPI-associated AIN:**

| Feature | PPI-AIN | Classic Drug-AIN |
|----|----|----|
| **Onset after initial exposure** | 2–3 months (median) | 1–3 weeks |
| **Rash/fever/eosinophilia** | Absent or minimal | Present in 10% |
| **Systemic symptoms** | None typically | Variable |
| **Urine sediment** | Pyuria, occasional WBC casts | WBC casts common |
| **Eosinophiluria** | Rare | Variable |
| **Recovery after cessation** | Often slow (weeks to months) | Faster (days to weeks) |
| **Steroid responsiveness** | Variable | Good if given early |

In a patient with unexplained AKI and normal complement levels, normal serologic workup, and lack of GN features, always verify PPI use. Discontinuation is the first intervention. If creatinine does not improve within 5–7 days, consider corticosteroids.

### 2.6 When to Perform Kidney Biopsy in Suspected AIN

**Indications for biopsy:** 1. **Diagnostic uncertainty:** Active sediment present but serologies are negative and diagnosis remains unclear 2. **No improvement after drug withdrawal:** If creatinine plateaus or worsens after stopping the presumed offending agent 3. **Consideration of corticosteroid therapy:** Some nephrologists biopsy to confirm AIN before giving high-dose steroids, especially if steroid risks are high 4. **Fever/rash/eosinophilia triad present:** Biopsy confirms diagnosis; guides prognosis

**Contraindications (relative):** - Solitary kidney (increased bleed risk; small needle biopsy possible) - Uncontrolled hypertension (HTN \>180/110 mmHg increases bleed risk) - Active bleeding diathesis or anticoagulation that cannot be reversed - Infection at biopsy site

**Timing:** - Biopsy in first 2 weeks after AKI onset is ideal (fresh infiltrate) - Delayed biopsy (\>4 weeks) may show fibrosis and chronic changes instead of acute infiltrate

### 2.7 Kidney Biopsy Findings: Light Microscopy and Immunofluorescence

**Light microscopy:** - **Interstitial inflammation:** Predominantly lymphocytes (T cells), occasional plasma cells and eosinophils - **Tubulitis:** Infiltrating cells within tubular epithelium; tubular basement membrane (TBM) intact - **Interstitial edema:** Acute swelling; no prominent fibrosis - **Glomeruli:** Typically normal or minimal changes (unless concurrent GN)

**Immunofluorescence (IF):** - Usually **negative or minimal staining** (this distinguishes AIN from immune GN) - Occasional **IgM, C3 in tubular basement membrane** (non-specific) - If linear IgG or strong granular IgA/IgG → suspect concurrent anti-GBM disease or IgA nephropathy

**Electron microscopy (EM):** - Not routinely needed - Shows podocyte effacement if concurrent FSGS or nephrotic component

### 2.8 AIN Treatment and Prognosis

**Immediate management:** 1. **Discontinue offending drug** (highest priority) 2. **Assess recovery:** Follow creatinine daily for 5–7 days

**If creatinine not improving after 5–7 days of drug cessation:** - Consider kidney biopsy (if diagnosis uncertain) - Consider **corticosteroids:** - Methylprednisolone 500 mg IV daily × 3 days, then oral prednisone 1 mg/kg (max 80 mg) daily × 3–4 weeks, then taper - Or: Oral prednisone 1 mg/kg/day × 4 weeks then taper - Evidence is mixed; benefit clearer if given within 2 weeks of onset and if eosinophilia/WBC casts present^([3,7](https://urinenephrology.org/mastery/aki-advanced/ain-gn-diagnostic-methodologies-review.html#verified-sources))

**Prognosis:** - Full recovery of GFR: 50–60% of patients - Partial recovery: 25–35% (residual CKD) - No recovery requiring dialysis: 5–10% - Worse prognosis: delayed presentation (\>3 weeks), advanced age, baseline CKD, need for dialysis at presentation

See detailed clinical guidance at acute interstitial nephritis review.

------------------------------------------------------------------------

## 3. Diagnostic Approach to Glomerulonephritis in AKI Setting

When AKI is accompanied by **RBC casts, dysmorphic RBCs, proteinuria, and/or hypertension,** GN becomes the leading diagnosis. Serologic evaluation is urgent and comprehensive.

### 3.1 Serologic Workup Panel

The **complete GN serologic panel** includes:

#### ANCA and ANCA-Associated Vasculitis^([11](https://urinenephrology.org/mastery/aki-advanced/ain-gn-diagnostic-methodologies-review.html#verified-sources))

    Panel:
    ├── c-ANCA (cytoplasmic) + PR3-ANCA
    │   └── Granulomatosis with polyangiitis (GPA, formerly Wegener's)
    │
    ├── p-ANCA (perinuclear) + MPO-ANCA
    │   └── Microscopic polyangiitis (MPA)
    │       Eosinophilic granulomatosis with polyangiitis (EGPA, formerly Churg-Strauss)
    │
    └── Negative ANCA
        └── Rules out pauci-immune ANCA vasculitis

**Clinical sensitivity/specificity:** - PR3-ANCA: Specific for GPA; positive in ~90% of GPA with active GN - MPO-ANCA: Highly specific for MPA/EGPA; positive in ~80% of MPA with GN

#### Anti-GBM (Goodpasture Syndrome)

See anti gbm disease review.

- **Serum anti-GBM antibody:** If positive, diagnostic of anti-GBM disease
- **Clinical presentation:** Pulmonary-renal syndrome (hemoptysis + GN) is classic; pulmonary hemorrhage in ~50%
- **Urgency:** RPGN with crescents; empiric treatment before confirmatory testing justified
- **IgG/IgM/IgA can all be present; IgG most common**

#### Lupus-Associated GN^([12](https://urinenephrology.org/mastery/aki-advanced/ain-gn-diagnostic-methodologies-review.html#verified-sources))

See Lupus Nephritis Treatment Evidence Review.

**Serology:** - **ANA:** Sensitive (\>95%) but not specific; positive in 15–20% of healthy individuals - **Anti-dsDNA:** Highly specific (\>95%) for SLE; correlates with lupus nephritis activity - **Anti-Smith (anti-Sm):** Specific for SLE but less sensitive - **Complement levels:** C3, C4 typically low in active lupus nephritis; normal in other GN types - **Anti-C1q:** May correlate with disease activity and complement activation

**Caveat — serologically quiet lupus:** See case discussion at Lupus Nephritis Renal First Serologically Quiet Case Report. - ANA and dsDNA can be negative at initial GN presentation - Biopsy often confirms lupus nephritis based on **full house IF pattern** (IgG, IgA, IgM, C3, C1q all positive) - Serial serology often becomes positive within weeks to months

#### Cryoglobulinemia (HCV-Associated)

See cryoglobulinemic gn review.

- **Serum cryoglobulins:** Type II (mixed cryoglobulinemia, 50–60% of all cryoglobulinemia)
- **Hepatitis C serology and RNA:** Critical; HCV drives disease in \>80% of mixed cryo
- **Rheumatoid factor:** Often elevated
- **Low C4 (normal C3):** Characteristic pattern
- **Clinical:** Palpable purpura (lower extremities), arthralgias, neuropathy common
- **Renal:** MPGN pattern on biopsy; hematuria + proteinuria

#### Paraprotein-Related and Light-Chain Disease

See lcdd mgrs review.

- **SPEP/UPEP:** Identifies monoclonal protein spike
- **Free light chains (FLC):** Kappa/lambda ratio abnormal in light-chain disease and light-chain GN
- **Immunofixation electrophoresis (IFE):** Confirms monoclonal protein type
- **Serum vs. urine FLC:** Serum FLC particularly important for rapidly progressive disease
- **Biopsy immunostaining:** Identifies light-chain type (kappa or lambda predominance)

#### Post-Infectious GN

See post infectious gn review.

- **ASO titer (antistreptolysin O):** Elevated in post-streptococcal GN (but insensitive if \>2 weeks from infection)
- **Anti-DNase B:** More sensitive than ASO if delayed presentation
- **Throat culture and rapid strep:** If active infection
- **Complement levels:** C3 typically low; C4 normal (important distinguisher from lupus)
- **Hepatitis B/C serology:** Different immune complex pattern; HBsAg positive in HBV-associated GN
- **Bacterial cultures:** Blood culture if endocarditis suspected

#### IgA Nephropathy

- **IgA serum levels:** Elevated in some but not diagnostic
- **No specific serologic marker**
- **Diagnosis by biopsy:** IgA deposition on IF (see Glomerular-Diseases section)
- **Complement: Normal C3/C4** (helps distinguish from post-infectious or lupus GN)

### 3.2 Complement Pattern Table: Differential Diagnosis at a Glance

This table is **essential** for rapid diagnostic reasoning^([13](https://urinenephrology.org/mastery/aki-advanced/ain-gn-diagnostic-methodologies-review.html#verified-sources)):

| **Low C3, Normal C4** | **Low C3 AND Low C4** | **Normal C3 and C4** |
|----|----|----|
| Post-infectious GN | **Lupus nephritis** | **ANCA vasculitis** (pauci-immune) |
| Membranoproliferative GN (MPGN) Type II | Cryoglobulinemia (Type II) | **Anti-GBM disease** (Goodpasture) |
| C3 glomerulonephritis (C3GN) | Severe post-infectious GN | **IgA nephropathy** |
| Endocarditis-associated GN |  | ANCA (less common low-complement variants) |
|  |  | Post-infectious GN (if early) |

This table drives decision-making. Once complement results return, the differential narrows dramatically. A normal C3 and C4 with RPGN and dysmorphic hematuria strongly favors ANCA or anti-GBM disease—both warrant empiric treatment before biopsy confirmation.

### 3.3 RPGN: The Emergency Diagnosis

**RPGN = Rapidly Progressive Glomerulonephritis**

**Definition:** GN with crescents involving ≥50% of glomeruli on light microscopy.

**Clinical hallmarks:** - **Rapid rise in creatinine:** Days to weeks - **Active urinary sediment:** RBC casts, dysmorphic RBCs, proteinuria - **Systemic symptoms variable:** May be absent (pauci-immune) or prominent (granulomatosis with polyangiitis)

**Three pathologic categories (define therapy):**

| Category | Pattern | Associated Diagnosis | Typical Treatment |
|----|----|----|----|
| **Anti-GBM** | Linear IgG on IF | Goodpasture, anti-GBM disease | Plasmapheresis + corticosteroids + cyclophosphamide |
| **Immune complex** | Granular IF (IgG, IgA, IgM, C3) | Lupus, post-infectious, IgA | Corticosteroids ± cyclophosphamide/rituximab |
| **Pauci-immune** | Minimal/negative IF (C3 only) | ANCA (GPA, MPA) | Corticosteroids + cyclophosphamide or rituximab |

**Critical point:** \> \[!warning\] \> **RPGN is a nephrology emergency.** Once crescentic GN is suspected (RBC casts + rapidly rising creatinine + active urine sediment), **start empiric treatment BEFORE biopsy returns.** Delay of even days can result in irreversible loss of renal function requiring long-term dialysis.

**Empiric treatment initiated while awaiting biopsy:** - **Pulse methylprednisolone:** 500 mg IV daily × 3 days - **Cyclophosphamide or rituximab:** Load dose (RTX preferred in current practice) - **Consider plasmapheresis** if pulmonary hemorrhage or severe oliguric AKI

------------------------------------------------------------------------

## 4. Case-Based Teaching

### 4.1 The Positive ANA in Infective Endocarditis

See Lupus vs IE Case Report.

**Clinical scenario:**

    Patient: 68-year-old male with fever, murmur, hematuria, ANA 1:1280
    Initial impression: "Lupus nephritis—start immunosuppression"
    Result if wrong: Worsening infection, abscess, embolic complications

**Key differentiators between IE and lupus:**

| Feature | Infective Endocarditis | Lupus Nephritis |
|----|----|----|
| **ANA** | Positive in 15–20% | \>95% positive |
| **Anti-dsDNA** | Negative | Positive in active disease |
| **Blood cultures** | **Positive** (key finding) | Negative |
| **Echocardiography** | Vegetation on valve | Normal or lupus-associated vegetations (rare) |
| **Complement levels** | Low C3, C4 (consumed by immune activation) | Low C3, C4 (lupus IC) |
| **Fever pattern** | Persistent, variable | May be absent |
| **Peripheral stigmata** | Splinter hemorrhages, Osler nodes, Janeway lesions | Not typical of IE |

**Clinical lesson:** - Always obtain **blood cultures** before antibiotics in fever + AKI - In IE, ANA can be positive due to polyclonal B-cell activation and circulating immune complexes - Anti-dsDNA is specific for lupus; if positive, supports lupus; if negative with high ANA, think IE - Echocardiography (TEE preferred) is diagnostic for IE; rules out lupus mimicry

### 4.2 Lupus Nephritis: Renal-First Presentation and Serologically Quiet Disease

See Lupus Nephritis Renal First Serologically Quiet Case Report.

**Clinical scenario:**

    Patient: 28-year-old female with AKI, RBC casts, proteinuria
    Labs: ANA 1:160 (borderline), dsDNA negative, C3 low, C4 normal
    Initial assessment: "Not lupus (negative dsDNA)"
    Biopsy result: Lupus nephritis, Class IV-S (diffuse proliferative)

**Serologically quiet lupus nephritis:** - Occurs in 5–10% of lupus patients with renal involvement - ANA may be negative or low-titer at presentation - dsDNA may be negative initially; converts to positive within weeks to months - **Diagnosis is by kidney biopsy showing full house IF pattern**

**IF pattern in lupus:** - **Full house:** IgG, IgA, IgM, C3, **C1q all positive** (pathognomonic) - C1q positivity correlates with proliferative forms and disease activity - Tubular basement membrane staining often prominent

**Management approach:** - Biopsy strongly considered if: - Active urinary sediment (RBC casts, dysmorphic RBCs) + renal dysfunction - Low complement levels (C3, C4 low) - Any positive autoantibody (even if dsDNA negative) - Biopsy needed to: - Confirm lupus nephritis - Classify (WHO Class I–VI) to guide therapy intensity - Assess chronicity (fibrosis, tubular atrophy) to estimate prognosis

------------------------------------------------------------------------

## 5. Kidney Biopsy: Indications, Contraindications, and Interpretation

### 5.1 Indications for Kidney Biopsy in AKI

**Diagnostic indications:**

1.  **Active sediment with negative serology:** RBC casts present, serologic workup negative (no ANCA, no anti-GBM, no lupus serology) — biopsy identifies etiology
2.  **Serologically quiet disease:** Suspected lupus or other immune GN with atypical serology
3.  **Uncertain ATN vs. AIN vs. GN:** Clinical presentation ambiguous; biopsy clarifies
4.  **Suspected drug-induced:** Biopsy confirms AIN before corticosteroids given
5.  **RPGN:** Rapid decline with crescents likely; biopsy categorizes (anti-GBM vs. immune complex vs. pauci-immune) to guide specific therapy

**Prognostic indications:**

1.  **Assess chronicity:** Fibrosis score, tubular atrophy severity predict recovery potential and guide steroid use
2.  **Baseline before treatment:** Certain MPGN or GPA cases benefit from biopsy to assess baseline inflammation vs. chronic changes

### 5.2 Contraindications to Kidney Biopsy

| Contraindication | Severity | Mitigation |
|----|----|----|
| **Solitary kidney** | Relative | Small-bore needle biopsy acceptable; ultrasound-guided; experienced operator |
| **Uncontrolled hypertension** | Relative | SBP \>180, DBP \>110 mmHg; control to \<160/100 before biopsy |
| **Anticoagulation** | Relative/Absolute | Warfarin: INR 2–3 OK; \>3 reverse first. DOAC: hold × 3–5 half-lives. Aspirin: continue. Dual antiplatelet: high bleed risk; discuss risks/benefits |
| **Thrombocytopenia** | Relative | Platelets \<50k: transfuse. Platelets 50–100k: acceptable if no bleeding diathesis |
| **Coagulopathy** | Relative | PT/PTT elevated; correct with FFP or reversal agents |
| **Active infection at biopsy site** | Absolute | Defer until resolved |
| **Skin/soft tissue infection systemically** | Relative | Systemic infection acceptable; local infection at site contraindication |

### 5.3 Biopsy Technique and Yield

**Standard percutaneous needle biopsy:** - **Ultrasound-guided or fluoroscopy-guided** (ultrasound preferred; real-time visualization) - **18-gauge needle** (standard); 20-gauge if bleeding risk - Obtain **2–3 core samples minimum:** 8–10 mm length optimal - **Light microscopy, immunofluorescence, and electron microscopy** from same tissue samples

**Success rate:** 95–98% diagnostic adequacy with experienced operator

**Post-biopsy hemorrhage risk:** 0.5–1% clinically significant bleeding; \<0.1% need intervention/transfusion

### 5.4 Pathologic Interpretation: What Each Modality Reveals

#### Light Microscopy (LM)

**Helps answer:** - Is there glomerulonephritis? (proliferation, crescent formation, necrosis) - If GN, what pattern? (endocapillary, extracapillary, etc.) - Are there tubular changes? (atrophy, necrosis, basement membrane changes) - Interstitial disease? (inflammation, fibrosis, edema) - Vascular disease? (arteriosclerosis, arteritis, intimal proliferation)

**Key findings in AKI:** - **AIN:** Interstitial infiltrate (lymphocytes, eosinophils), tubulitis, edema; glomeruli normal or minimally changed - **GN:** Glomerular proliferation, crescent formation, necrosis; mesangial expansion possible

#### Immunofluorescence (IF)

**Tells you the immune composition — critical for narrowing diagnosis:**

| IF Pattern | Diagnosis |
|----|----|
| **Linear IgG along GBM** | Anti-GBM disease (Goodpasture) |
| **Granular IgG, IgA, IgM, C3 + C1q** | Lupus nephritis (full house) |
| **Granular IgA (dominant)** | IgA nephropathy |
| **Granular IgM (dominant) + C3** | Membranoproliferative GN Type II, IgM nephropathy |
| **C3-dominant (IgG, IgM minimal/absent)** | C3 glomerulonephritis, post-infectious GN, membranoproliferative GN Type I |
| **Pauci-immune (C3 ± minimal Ig)** | ANCA vasculitis (GPA, MPA) |
| **Negative or minimal staining** | AIN, ANCA vasculitis (sometimes), seronegative GN |
| **Tubular basement membrane staining** | Lupus (C1q, IgG common), anti-GBM |

#### Electron Microscopy (EM)

**Ultrastructure reveals:**

| Finding | Diagnosis |
|----|----|
| **Subepithelial humps** | Post-infectious GN (electron-dense deposits) |
| **Subendothelial deposits** | Lupus, IgA nephropathy |
| **Basement membrane splitting (basket-weave)** | Alport syndrome |
| **Dense intramembranous deposits** | Membranoproliferative GN Type II (membranoproliferative GN with intramembranous deposits) |
| **Podocyte effacement** | Focal segmental glomerulosclerosis (FSGS), minimal change, collapsing GN |
| **Electron-dense deposits** | Immune complex GN (lupus, IgA, post-infectious) |
| **Absence of deposits (pauci-immune)** | ANCA vasculitis |

------------------------------------------------------------------------

## 6. Integrated Diagnostic Algorithm: From Suspicion to Treatment

### 6.1 Flowchart: AKI with Active Sediment

    AKI Diagnosis
        ↓
    Urinalysis with microscopy
        ↓
    ─────────────────────────────────────
    │
    ├─ INACTIVE sediment (no casts, no hematuria)
    │   └─→ ATN vs. Prerenal
    │       → FeNa, BUN:Cr, trial of fluids
    │
    └─ ACTIVE sediment (casts, hematuria, pyuria, WBC casts)
        ↓
        ├─ RBC CASTS or dysmorphic RBCs?
        │  ├─ YES → GN likely
        │  │   └─→ [See GN algorithm below]
        │  │
        │  └─ NO, but WBC casts + sterile pyuria?
        │     ├─ YES → AIN likely
        │     │   └─→ [See AIN algorithm below]
        │     │
        │     └─ NO → Mixed or uncertain
        │         └─→ [Obtain serologies + consider biopsy]

### 6.2 AIN Diagnostic Algorithm

    Suspected AIN (pyuria + WBC casts)
        ↓
    Step 1: Drug Timeline Review
    ├─ Drug exposure 1–3 weeks before AKI?
    │  └─ Beta-lactam, sulfonamide, NSAID, FQ → LIKELY
    ├─ PPI use for any duration?
    │  └─ Any duration → POSSIBLE (delayed presentation)
    ├─ Other drugs (statins, diuretics, allopurinol)?
    │  └─ Consider, but less common
        ↓
    Step 2: Clinical Features
    ├─ Rash, fever, eosinophilia?
    │  └─ If present (10% of cases) → Supportive
    ├─ Mucosal ulcers, arthralgias?
    │  └─ → Supportive
        ↓
    Step 3: Laboratory Testing
    ├─ Urine eosinophils (Hansel stain)?
    │  └─ If positive → Highly specific
    ├─ Proteinuria?
    │  └─ <1 g/day expected
    ├─ Eosinophilia (blood)?
    │  └─ Present in ~30% (not sensitive)
        ↓
    Step 4: Decision Tree

      ┌─────────────────────────────────────────────────┐
      │ Is diagnosis certain (classic history + features)? │
      └─────────────────────────────────────────────────┘
           ↙ YES              ↘ NO / UNCERTAIN
           │                   │
           ↓                   ↓
        STOP offending    Consider BIOPSY if:
        drug               • Diagnosis uncertain
           │               • No improvement after drug stop (5–7 days)
           ↓               • Considering corticosteroids
        Monitor Cr daily
           │
           ├─ Cr improves → Observe, support renal function
           │
           └─ Cr plateaus/worsens → BIOPSY + Consider steroids
                  ↓
               [See Treatment]

### 6.3 GN Diagnostic Algorithm

    Suspected GN (RBC casts / dysmorphic RBCs)
        ↓
    URGENT: Obtain comprehensive serology STAT
        ├─ C3, C4 (complement)
        ├─ ANCA (c-ANCA + p-ANCA, with PR3/MPO reflex)
        ├─ Anti-GBM
        ├─ ANA, anti-dsDNA
        ├─ Hepatitis B/C, HIV
        ├─ ASO titer, anti-DNase B (if post-infectious suspected)
        ├─ Cryoglobulins (if vasculitis suspected)
        ├─ SPEP/UPEP/FLC (if monoclonal disease suspected)
        └─ Blood cultures (if endocarditis suspected)
        ↓
        ├─ RPGN features? (Creatinine rising >0.3 mg/dL/day, oliguria, hemoptysis)
        │  └─ YES → START EMPIRIC THERAPY immediately
        │       ├─ Methylprednisolone 500 mg IV × 3 days
        │       ├─ Cyclophosphamide or Rituximab
        │       └─ Consider plasmapheresis
        │       └─→ Continue therapy while awaiting biopsy
        │
        └─ Non-RPGN features? (Stable renal function, non-oliguric)
           └─ YES → Await serologic results (24–48 hours)
        ↓
        ┌──────────────────────────────────────────────────┐
        │ Interpret Complement Pattern + Serology           │
        └──────────────────────────────────────────────────┘
        │
        ├─ c-ANCA/PR3 + normal complement → GPA
        │  └─→ Biopsy shows: ANCA vasculitis, crescents, pauci-immune IF
        │  └─→ Treatment: RTX or CYC + corticosteroids
        │
        ├─ p-ANCA/MPO + normal complement → MPA
        │  └─→ Biopsy shows: Pauci-immune crescentic GN
        │  └─→ Treatment: RTX or CYC + corticosteroids
        │
        ├─ Anti-GBM (+) → Goodpasture syndrome
        │  └─→ Biopsy shows: Linear IgG along GBM, crescents
        │  └─→ Treatment: Plasmapheresis + CYC + corticosteroids
        │  └─→ Urgent treatment; prognosis poor if dialysis-dependent
        │
        ├─ ANA (+), anti-dsDNA (+), C3 & C4 LOW → Lupus nephritis
        │  └─→ Biopsy shows: Full house IF, class I–VI
        │  └─→ Treatment: Class-dependent; MMF or CYC + steroids typical
        │
        ├─ ANA low/borderline, C3/C4 normal/low, dsDNA (–) → Serologically quiet or other GN
        │  └─→ BIOPSY needed for diagnosis
        │  └─→ Possible diagnoses:
        │       ├─ Lupus nephritis (renal-first)
        │       ├─ IgA nephropathy
        │       ├─ Post-infectious GN
        │       └─ Other MPGN
        │
        ├─ Low C3 (normal C4), no ANCA/anti-GBM/ANA → Post-infectious GN likely
        │  └─→ History: Recent strep infection, IVDU, endocarditis risk
        │  └─→ ASO/anti-DNase B positive
        │  └─→ Treatment: Supportive; most resolve spontaneously
        │
        ├─ Cryoglobulins (+), HCV (+), low C4 → Cryoglobulinemia
        │  └─→ Biopsy shows: MPGN pattern, cryoglobulin deposits
        │  └─→ Treatment: Antiviral (DAA), corticosteroids, RTX if severe
        │
        └─ SPEP/UPEP monoclonal spike, FLC elevated → Paraprotein-related GN
           └─→ Biopsy shows: LC-dominant deposition, membranoproliferative pattern
           └─→ Treatment: Hematology referral, chemotherapy or proteasome inhibitor
        ↓
    PERFORM KIDNEY BIOPSY if:
    ├─ Diagnosis remains uncertain after serologies
    ├─ Serology negative but sediment active
    ├─ Need to classify GN severity (for treatment intensity)
    ├─ Assessing chronicity/prognosis
    └─ RPGN with atypical features
        ↓
        Based on biopsy categorization:
        ├─ IF category (anti-GBM vs. immune complex vs. pauci-immune)
        ├─ LM chronicity score
        └─ → Refine therapy and prognosis

------------------------------------------------------------------------

## 7. When to Start Treatment BEFORE Biopsy Results

Empiric therapy is justified in RPGN because delay results in irreversible renal failure.

**Scenarios requiring immediate treatment (do not wait for biopsy):**

1.  **RPGN with crescents on initial biopsy:** If biopsy is obtained immediately and shows crescentic GN, treat immediately
2.  **Suspected RPGN based on clinical features:**
    - RBC casts + rapidly rising creatinine (\>0.5 mg/dL/day)
    - Oliguria (urine output \<400 mL/day)
    - Pulmonary hemorrhage (hemoptysis, infiltrates on imaging)
    - → Start empiric induction therapy while biopsy being processed

**Empiric induction regimen:** - **Corticosteroids:** Methylprednisolone 500 mg IV daily × 3 days, then oral prednisone - **Immunosuppression:** - Rituximab 375 mg/m² IV weekly × 4 weeks (preferred; fewer infections than CYC), OR - Cyclophosphamide 0.5–1 g/m² IV monthly × 3–6 months - **Plasmapheresis:** Initiated if anti-GBM suspected or pulmonary hemorrhage present

**Adjust after biopsy confirmation:** - If anti-GBM (linear IF): Continue plasmapheresis × 7–14 sessions; RTX or CYC - If ANCA (pauci-immune): Continue RTX or CYC; plasmapheresis role limited - If immune complex (granular IF): RTX or CYC; plasmapheresis for severe pulmonary hemorrhage

------------------------------------------------------------------------

## 8. Key Clinical Pearls and Practice Points

- **The urinalysis is your roadmap:** WBC casts = think AIN; RBC casts = think GN
- **Timing matters:** Drug-induced AIN typically 1–3 weeks; PPIs are the exception (months to years)
- **Sterile pyuria is essential:** Always check urine culture; UTI is not AIN
- **Complement patterns narrow the differential:** Low C3 + normal C4 → post-infectious; low C3 + low C4 → lupus; normal both → ANCA or anti-GBM
- **Serologically quiet disease is real:** Negative dsDNA or ANA does NOT exclude lupus nephritis; biopsy may show full house IF
- **RPGN is a nephrology emergency:** Empiric treatment is justified before biopsy confirmation if clinical suspicion is high
- **Biopsy timing matters:** Early biopsy (first 2 weeks) captures active infiltrate; delayed biopsy may show fibrosis and underestimate disease severity
- **Corticosteroids in AIN:** Give early (within 2 weeks) if no improvement after drug withdrawal; efficacy uncertain but data support trial if severe
- **Post-biopsy follow-up:** Continue supportive care, avoid nephrotoxins, monitor for complications (infection, bleed, allergic reaction to contrast if imaging done)

------------------------------------------------------------------------

## Related Resources

**AKI Diagnostic Framework:** - aki comprehensive evaluation review — Full AKI diagnostic approach - aki staging classification review — KDIGO classification and prognosis - aki workup summary — Practical summary table

**AIN-Specific Reviews:** - acute interstitial nephritis review — Comprehensive AIN review with management - ppi kidney report — PPI-associated AIN detailed analysis - B2M AIN Comprehensive Review — Urine biomarkers in AIN

**GN-Specific Reviews:** - Lupus Nephritis Treatment Evidence Review — Lupus nephritis diagnosis and treatment - Lupus Nephritis Renal First Serologically Quiet Case Report — Serologically quiet lupus case - anti gbm disease review — Anti-GBM (Goodpasture) syndrome - post infectious gn review — Post-infectious and endocarditis-associated GN - cryoglobulinemic gn review — Cryoglobulinemia and HCV-associated GN - lcdd mgrs review — Light-chain disease and monoclonal gammopathy-related GN

**Case-Based Learning:** - Lupus vs IE Case Report — Differentiating ANA-positive IE from lupus nephritis

**Glomerular Diseases Hub:** - Glomerular Hub — Index to all glomerulonephritis content

------------------------------------------------------------------------

### Sources

1.  Muriithi AK, Leung N, Valeri AM, et al. Clinical characteristics, causes and outcomes of acute interstitial nephritis in the elderly. *Kidney Int*. 2015;87(2):458–464. [PubMed](https://pubmed.ncbi.nlm.nih.gov/25185078/) (PMID 25185078)
2.  Muriithi AK, Nasr SH, Leung N. Utility of urine eosinophils in the diagnosis of acute interstitial nephritis. *Clin J Am Soc Nephrol*. 2013;8(11):1857–1862. [PubMed](https://pubmed.ncbi.nlm.nih.gov/24052222/) (PMID 24052222)
3.  Praga M, González E. Acute interstitial nephritis. *Kidney Int*. 2010;77(11):956–961. [PubMed](https://pubmed.ncbi.nlm.nih.gov/20336051/) (PMID 20336051)
4.  Rossert J. Drug-induced acute interstitial nephritis. *Kidney Int*. 2001;60(2):804–817. [PubMed](https://pubmed.ncbi.nlm.nih.gov/11473672/) (PMID 11473672)
5.  Perazella MA, Markowitz GS. Drug-induced acute interstitial nephritis. *Nat Rev Nephrol*. 2010;6(8):461–470. [PubMed](https://pubmed.ncbi.nlm.nih.gov/20517290/) (PMID 20517290)
6.  Perazella MA. The urine sediment as a biomarker of kidney disease. *Am J Kidney Dis*. 2015;66(5):748–755. [PubMed](https://pubmed.ncbi.nlm.nih.gov/25943719/) (PMID 25943719)
7.  Perazella MA, Rosner MH. Drug-induced acute kidney injury. *Clin J Am Soc Nephrol*. 2022;17(8):1220–1233. [PubMed](https://pubmed.ncbi.nlm.nih.gov/35273009/) (PMID 35273009)
8.  Xie Y, Bowe B, Li T, et al. Proton pump inhibitors and risk of incident CKD and progression to ESRD. *J Am Soc Nephrol*. 2016;27(10):3153–3163. [PubMed](https://pubmed.ncbi.nlm.nih.gov/27080976/) (PMID 27080976)
9.  Lazarus B, Chen Y, Wilson FP, et al. Proton pump inhibitor use and the risk of chronic kidney disease. *JAMA Intern Med*. 2016;176(2):238–246. [PubMed](https://pubmed.ncbi.nlm.nih.gov/26752337/) (PMID 26752337)
10. Cortazar FB, Kibbelaar ZA, Glezerman IG, et al. Clinical features and outcomes of immune checkpoint inhibitor–associated AKI: a multicenter study. *J Am Soc Nephrol*. 2020;31(2):435–446. [PubMed](https://pubmed.ncbi.nlm.nih.gov/31896554/) (PMID 31896554)
11. Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. *Arthritis Rheum*. 2013;65(1):1–11. [PubMed](https://pubmed.ncbi.nlm.nih.gov/23045170/) (PMID 23045170)
12. Hahn BH, McMahon MA, Wilkinson A, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. *Arthritis Care Res (Hoboken)*. 2012;64(6):797–808. [PubMed](https://pubmed.ncbi.nlm.nih.gov/22556106/) (PMID 22556106)
13. Sethi S, Fervenza FC. Membranoproliferative glomerulonephritis—a new look at an old entity. *N Engl J Med*. 2012;366(12):1119–1131. [PubMed](https://pubmed.ncbi.nlm.nih.gov/22435371/) (PMID 22435371)
14. Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. *Nephron Clin Pract*. 2012;120(4):c179–c184. [PubMed](https://pubmed.ncbi.nlm.nih.gov/22890468/) (PMID 22890468)

------------------------------------------------------------------------

*Last updated: 2026-05-04* *For questions or updates, contact: [send a comment or correction to the author](https://urinenephrology.org/author-feedback.html?page=%2Fmastery%2Faki-advanced%2Fain-gn-diagnostic-methodologies-review.html&title=AIN+and+GN+Diagnostic+Methodologies%3A+From+Clinical+Suspicion+to+Kidney+Biopsy+%E2%80%94+Medical+Education+Handout)*


---

[Website version](https://urinenephrology.org/mastery/aki-advanced/ain-gn-diagnostic-methodologies-review.html) · Markdown synchronized October 3, 2026.